Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance

  • Kim, Albert E.
  • Lou, Kevin W.
  • Giobbie-Hurder, Anita
  • Chang, Ken
  • Gidwani, Mishka
  • Hoebel, Katharina
  • Patel, Jay B.
  • Cleveland, Mason C.
  • Singh, Praveer
  • Bridge, Christopher P.
  • Rakin Ahmed, Syed
  • Bearce, Benjamin A.
  • Liu, William
  • Lee, Eudocia Q.
  • Fuster García, Elíes|||0000-0002-0716-8960
[EN] Background. We recently conducted a phase 2 trial (NCT028865685) evaluating intracranial efficacy of pembrolizumab for brain metastases (BM) of diverse histologies. Our study met its primary efficacy endpoint and illustrates that pembrolizumab exerts promising activity in a select group of patients with BM. Given the importance of aberrant vasculature in mediating immunosuppression, we explored the relationship between immune checkpoint inhibitor (ICI) efficacy and vascular architecture in the hopes of identifying potential mechanisms of intracranial ICI response or resistance for BM. Methods. Using Vessel Architectural Imaging, a histologically validated quantitative metric for in vivo tumor vascular physiology, we analyzed dual-echo DSC/DCE MRI for 44 patients on trial. Tumor and peri-tumor cerebral blood volume/flow, vessel size, arterial and venous dominance, and vascular permeability were measured before and after treatment with pembrolizumab. Results. BM that progressed on ICI were characterized by a highly aberrant vasculature dominated by largecaliber vessels. In contrast, ICI-responsive BM possessed a more structurally balanced vasculature consisting of both small and large vessels, and there was a trend toward a decrease in under-perfused tissue, suggesting a reversal of the negative effects of hypoxia. In the peri-tumor region, the development of smaller blood vessels, consistent with neo-angiogenesis, was associated with tumor growth before radiographic evidence of contrast enhancement on anatomical MRI. Conclusions. This study, one of the largest functional imaging studies for BM, suggests that vascular architecture is linked with ICI efficacy. Studies identifying modulators of vascular architecture, and effects on immune activity, are warranted and may inform future combination treatments., A.E.K. is supported by an American Brain Tumor Association Basic Research Fellowship In Honor of Paul Fabbri, the William G. Kaelin, Jr., MD, Physician-Scientist Award of the Damon Runyon Cancer Research Foundation, American Association for Cancer Research Breast Cancer Research Fellowship, and American Society of Clinical Oncology Young Investigator Award. E.F.G. was supported by the European Union s Horizon 2020 Programme: Marie Sklodowska-Curie grant agreement No 844646-GLIOHAB and Spanish State Research Agency, Subprogram for Knowledge Generation (PROGRESS, No PID2021-127110OA-I00). P.K.B is supported by the NCI (1R01CA227156-01, 5R21CA220253-02, and 1R01CA244975-01), Damon Runyon Cancer Research Foundation, and Breast Cancer Research Foundation. Y.Y. is supported by the NIH (1R21AG067562-01 and 1R21GM137227-01). K.E.E. is supported by the European Union's Horizon 2020 Programme: ERC Grant Agreement No. 758657-ImPRESS, South-Eastern Norway Regional Health Authority (Grant Agreements No. 2016102, 2017073, 2013069), and the Norwegian Cancer Society and the FRIPRO Grant Agreements No. 261984, 303249). E.R.G. is supported by R01CA211238-01 and R01CA244975.